{
    "clinical_study": {
        "@rank": "23359", 
        "arm_group": [
            {
                "arm_group_label": "AC-170 0.24%", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AC-170 0%", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24%\n      compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis\n      in the conjunctival allergen challenge (CAC) model."
        }, 
        "brief_title": "A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle", 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  positive bilateral conjunctival allergen challenge (CAC) reaction\n\n        Exclusion Criteria:\n\n          -  known contraindications or sensitivities to the study medication or its components\n\n          -  any ocular condition that, in the opinion of the investigator, could affect the\n             subjects safety trial parameters\n\n          -  use of disallowed medication during the period indicated prior to the enrollment or\n             during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881113", 
            "org_study_id": "13-100-0002"
        }, 
        "intervention": [
            {
                "arm_group_label": "AC-170 0.24%", 
                "description": "1 drop in each eye at 2 separate times during a 14 day period", 
                "intervention_name": "AC-170 0.24%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AC-170 0%", 
                "description": "1 drop in each eye at 2 separate times during a 14 day period", 
                "intervention_name": "AC-170 0%", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mason", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Ocular itching at defined time points up to 2 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 14"
            }, 
            {
                "measure": "Ocular redness at defined time points up to 2 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Aciex Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aciex Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}